Senthil Damodaran

1.5k citations
76 papers · 777 · 1 hit paper · h-index 15

Impact in

  • Oncology top 5%
    • HER2/EGFR in Cancer Research
    • PARP inhibition in cancer therapy
    • Cancer Treatment and Pharmacology
    • Cancer-related Molecular Pathways
    • Breast Cancer Treatment Studies
    • Cancer Genomics and Diagnostics

Papers in

    • HER2/EGFR in Cancer Research 22
    • Cancer Treatment and Pharmacology 13
    • PARP inhibition in cancer therapy 9
    • Cancer-related Molecular Pathways 6
    • Advanced Breast Cancer Therapies 23

Senthil Damodaran

68 papers receiving 771 citations

Senthil Damodaran's Hit Papers

Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study 2024 · 84 citations
840+1Years since publication255075

Peers

Senthil Damodaran
Comparison fields: 5 of 55
  • Oncology 472
  • Cancer Research 179
  • Pulmonary and Respiratory Medicine 250
  • Radiology, Nuclear Medicine and Imaging 103
  • Genetics 48
Replace Gerrit K. Hooijer with:
Gerrit K. Hooijer Netherlands
Vadim S. Koshkin United States
Abraham C.F. Leung United States
Joely J. Irlam United Kingdom
Lars Schüttrumpf Germany
Leonie Voorwerk Netherlands
Marissa S. Mattar United States
Adam B. Aronson United States
Stephanie Yoon United States
Theresa Link Germany
Senthil Damodaran relative to Gerrit K. Hooijer Netherlands Gerrit K. Hooijer's profile →
Citations per field
00.5×5.4×
Gerrit K. Hooijer · 1×
Citations per year

Countries citing papers authored by Senthil Damodaran

Since Specialization
Citations

This map shows the geographic impact of Senthil Damodaran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Senthil Damodaran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Senthil Damodaran more than expected).

Fields of papers citing papers by Senthil Damodaran

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Senthil Damodaran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Senthil Damodaran. The network helps show where Senthil Damodaran may publish in the future.

Co-authors

The 25 scholars most cited alongside Senthil Damodaran, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Senthil Damodaran Line = papers co-authored together Senthil Damodaran links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 76 papers — load more, or switch the sort, to bring in the rest.

#Work
1 2019146
2
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
Hit paper breakdown →
202484
3 202250
4 202237
5 202227
6 202327
7 202327
8 202226
9 202024
10 201923
11 201822
12 202320
13 202118
14 202317
15 202317
16 202114
17 201413
18 202312
19 202512
20 201912

About Senthil Damodaran

Senthil Damodaran is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 76 papers that have together received 777 indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (23 papers), HER2/EGFR in Cancer Research (22 papers), Cancer Genomics and Diagnostics (16 papers), Cancer Treatment and Pharmacology (13 papers), Breast Cancer Treatment Studies (12 papers), PARP inhibition in cancer therapy (9 papers), BRCA gene mutations in cancer (8 papers) and Cancer-related Molecular Pathways (6 papers). The work is most often cited by research in Oncology (472 citations), Cancer Research (179 citations), Pulmonary and Respiratory Medicine (250 citations), Radiology, Nuclear Medicine and Imaging (103 citations) and Genetics (48 citations). Senthil Damodaran has collaborated with scholars based in United States, Japan and United Kingdom. Frequent co-authors include Funda Meric‐Bernstam, Debu Tripathy, Stacy L. Moulder, Jennifer K. Litton, Nuhad K. Ibrahim, Rashmi K. Murthy, Banu Arun, Aditya Bardia, Beatriz E. Adrada and Elizabeth A. Mittendorf. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, Clinical Cancer Research and ESMO Open.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact